Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.0 million.

  • Lipocine's Cash from Operations fell 539.45% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 391.92%. This contributed to the annual value of -$1.2 million for FY2024, which is 8970.81% up from last year.
  • Per Lipocine's latest filing, its Cash from Operations stood at -$3.0 million for Q3 2025, which was down 539.45% from -$1.9 million recorded in Q2 2025.
  • Over the past 5 years, Lipocine's Cash from Operations peaked at $9.0 million during Q4 2021, and registered a low of -$7.0 million during Q3 2021.
  • Its 5-year average for Cash from Operations is -$1.9 million, with a median of -$2.6 million in 2023.
  • In the last 5 years, Lipocine's Cash from Operations skyrocketed by 34414.95% in 2021 and then tumbled by 18179.61% in 2025.
  • Quarter analysis of 5 years shows Lipocine's Cash from Operations stood at $9.0 million in 2021, then crashed by 120.44% to -$1.8 million in 2022, then dropped by 9.97% to -$2.0 million in 2023, then skyrocketed by 184.16% to $1.7 million in 2024, then tumbled by 275.43% to -$3.0 million in 2025.
  • Its Cash from Operations stands at -$3.0 million for Q3 2025, versus -$1.9 million for Q2 2025 and -$2.0 million for Q1 2025.